Back to top
more

Alder BioPharmaceuticals, Inc. (ALDR)

(Delayed Data from NSDQ)

$12.28 USD

12.28
1,614,471

+0.04 (0.33%)

Updated May 3, 2019 04:00 PM ET

After-Market: $12.28 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Options Traders Expect Huge Moves in Alder Biopharmaceuticals (ALDR) Stock

by Zacks Equity Research

Investors in Alder Biopharmaceuticals (ALDR) need to pay close attention to the stock based on moves in the options market lately.

    Teva to Discontinue a Fremanezumab Study on Cluster Headache

    by Zacks Equity Research

    Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.

      Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod

      by Zacks Equity Research

      Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.

        Alder BioPharmaceuticals (ALDR) Jumps: Stock Rises 15.5%

        by Zacks Equity Research

        Alder BioPharmaceuticals, Inc. (ALDR) was a big mover last session, as the company saw its shares more than 15% on the day amid huge volumes.

          Alder's Shares Dip Despite Positive Migraine Trial Results

          by Zacks Equity Research

          Alder Biopharmaceuticals, Inc.'s (ALDR) shares plummeted almost 28% despite the announcement of positive top line results from phase III study, evaluating its lead pipeline candidate eptinezumab for prevention of frequent episodic migraine.

            Implied Volatility Surging for Alder Biopharmaceuticals (ALDR) Stock Options

            by Zacks Equity Research

            Alder Biopharmaceuticals (ALDR) needs Investors to pay close attention to the stock based on moves in the options market lately.

              Alder BioPharmaceuticals (ALDR) Looks Good: Stock Adds 10.7% in Session

              by Zacks Equity Research

              Alder BioPharmaceuticals' (ALDR) nearly 11% price rise in the last session increases the inquisitiveness for the stock. Read on to know more.

                Lilly's Migraine Drug Phase III Trials Meet Primary Endpoint

                by Zacks Equity Research

                Eli Lilly and Company (LLY) recently announced that its migraine candidate, galcanezumab, met primary endpoint in phase III studies